WWM
SRPT icon

Willingdon Wealth Management’s Sarepta Therapeutics SRPT Stock Holding History

Willingdon Wealth Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-4
Closed – – 519
2019
Q3 		$0 Buy
+4
New +$472 ﹤0.01% 537

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Willingdon Wealth Management's SRPT Position: Q4 2019 in Review

Willingdon Wealth Management sold out of Sarepta Therapeutics (SRPT) in Q4 2019, closing a stake of 4 shares.

Willingdon Wealth Management first reported a position in SRPT in Q3 2019 and held it in 1 quarter. The position peaked at $0 in Q3 2019. 389 funds tracked by Wall St. Rank hold SRPT as of Q4 2019.

  • Willingdon Wealth Management reported no remaining Sarepta Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Willingdon Wealth Management sold 4 Sarepta Therapeutics shares in Q4 2019.
  • Willingdon Wealth Management first reported a position in Sarepta Therapeutics in Q3 2019 and held it in 1 quarter.
  • Willingdon Wealth Management's Sarepta Therapeutics position peaked at $0 in Q3 2019.
  • 389 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2019.

Based on Willingdon Wealth Management's 13F filing for Q4 2019, filed 10 Feb 2020.